TQB2934

· Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for TQB2934, covering 2025-12-11 to 2026-01-02. Get the full timeline:

Most recent: Clinical Trial Update: Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients [Phase 1, Phase 2]

See pricing